Cargando…
What's new in critical illness and injury science? An evidence-based analysis of the impact of Janus Kinase inhibitors on 28-day mortality in patients admitted with COVID-19
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Wolters Kluwer - Medknow
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8547681/ https://www.ncbi.nlm.nih.gov/pubmed/34760655 http://dx.doi.org/10.4103/ijciis.ijciis_80_21 |
| _version_ | 1784590426717552640 |
|---|---|
| author | Miller, Andrew C. D'Silva, Yannick A. |
| author_facet | Miller, Andrew C. D'Silva, Yannick A. |
| author_sort | Miller, Andrew C. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8547681 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Wolters Kluwer - Medknow |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-85476812021-11-09 What's new in critical illness and injury science? An evidence-based analysis of the impact of Janus Kinase inhibitors on 28-day mortality in patients admitted with COVID-19 Miller, Andrew C. D'Silva, Yannick A. Int J Crit Illn Inj Sci Editorial Wolters Kluwer - Medknow 2021 2021-09-25 /pmc/articles/PMC8547681/ /pubmed/34760655 http://dx.doi.org/10.4103/ijciis.ijciis_80_21 Text en Copyright: © 2021 International Journal of Critical Illness and Injury Science https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
| spellingShingle | Editorial Miller, Andrew C. D'Silva, Yannick A. What's new in critical illness and injury science? An evidence-based analysis of the impact of Janus Kinase inhibitors on 28-day mortality in patients admitted with COVID-19 |
| title | What's new in critical illness and injury science? An evidence-based analysis of the impact of Janus Kinase inhibitors on 28-day mortality in patients admitted with COVID-19 |
| title_full | What's new in critical illness and injury science? An evidence-based analysis of the impact of Janus Kinase inhibitors on 28-day mortality in patients admitted with COVID-19 |
| title_fullStr | What's new in critical illness and injury science? An evidence-based analysis of the impact of Janus Kinase inhibitors on 28-day mortality in patients admitted with COVID-19 |
| title_full_unstemmed | What's new in critical illness and injury science? An evidence-based analysis of the impact of Janus Kinase inhibitors on 28-day mortality in patients admitted with COVID-19 |
| title_short | What's new in critical illness and injury science? An evidence-based analysis of the impact of Janus Kinase inhibitors on 28-day mortality in patients admitted with COVID-19 |
| title_sort | what's new in critical illness and injury science? an evidence-based analysis of the impact of janus kinase inhibitors on 28-day mortality in patients admitted with covid-19 |
| topic | Editorial |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8547681/ https://www.ncbi.nlm.nih.gov/pubmed/34760655 http://dx.doi.org/10.4103/ijciis.ijciis_80_21 |
| work_keys_str_mv | AT millerandrewc whatsnewincriticalillnessandinjuryscienceanevidencebasedanalysisoftheimpactofjanuskinaseinhibitorson28daymortalityinpatientsadmittedwithcovid19 AT dsilvayannicka whatsnewincriticalillnessandinjuryscienceanevidencebasedanalysisoftheimpactofjanuskinaseinhibitorson28daymortalityinpatientsadmittedwithcovid19 |